Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α2-adrenergic and serotonin2C receptors:: a comparison with citalopram

被引:140
作者
Millan, MJ
Gobert, A
Rivet, JM
Adhumeau-Auclair, A
Cussac, D
Newman-Tancredi, A
Dekeyne, A
Nicolas, JP
Lejeune, F
机构
[1] Ctr Rech Croissy, Inst Rech Servier, Dept Psychopharmacol, F-78290 Paris, France
[2] Ctr Rech Croissy, Inst Rech Servier, Dept Mol & Cellular Pharmacol, F-78290 Paris, France
关键词
depression; frontal cortex; hippocampus; nucleus accumbens; selective serotonin reuptake inhibitor;
D O I
10.1046/j.1460-9568.2000.00982.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Mirtazapine displayed marked affinity for cloned, human alpha(2A)-adrenergic (AR) receptors at which it blocked noradrenaline (NA)-induced stimulation of guanosine-5'-O-(3-[S-35]thio)-triphosphate ([S-35]-GTP gamma S) binding. Similarly, mirtazapine showed high affinity for cloned, human serotonin (5-HT)(2C) receptors at which it abolished 5-HT-induced phosphoinositide generation. Alpha(2)-AR antagonist properties were revealed in vivo by blockade of UK-14,304-induced antinociception, while antagonist actions at 5-HT2C receptors were demonstrated by blockade of Ro 60 0175-induced penile erections and discriminative stimulus properties. Mirtazapine showed negligible affinity for 5-HT reuptake sites, in contrast to the selective 5-HT reuptake inhibitor, citalopram. In freely moving rats, in the dorsal hippocampus, frontal cortex (FCX), nucleus accumbens and striatum, citalopram increased dialysate levels of 5-HT, but not dopamine (DA) and NA. On the contrary, mirtazapine markedly elevated dialysate levels of NA and, in FCX, DA, whereas 5-HT was not affected. Citalopram inhibited the firing rate of serotonergic neurons in dorsal raphe nucleus, but not of dopaminergic neurons in the ventral tegmental area, nor adrenergic neurons in the locus coeruleus. Mirtazapine, in contrast, enhanced the firing rate of dopaminergic and adrenergic, but not serotonergic, neurons. Following 2 weeks administration, the facilitatory influence of mirtazapine upon dialysate levels of DA and NA versus 5-HT in FCX was maintained, and the influence of citalopram upon FCX levels of 5-HT versus DA and NA was also unchanged. Moreover, citalopram still inhibited, and mirtazapine still failed to influence, dorsal raphe serotonergic neurons. In conclusion, in contrast to citalopram, mirtazapine reinforces frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission. These actions reflect antagonist properties at alpha(2A)-AR and 5-HT2C receptors.
引用
收藏
页码:1079 / 1095
页数:17
相关论文
共 134 条
[1]   EVIDENCE FOR NOREPINEPHRINE-MEDIATED COLLATERAL INHIBITION OF LOCUS COERULEUS NEURONS [J].
AGHAJANIAN, GK ;
CEDARBAUM, JM ;
WANG, RY .
BRAIN RESEARCH, 1977, 136 (03) :570-577
[2]   Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat [J].
Ainsworth, K ;
Smith, SE ;
Zetterström, TSC ;
Pei, Q ;
Franklin, M ;
Sharp, T .
PSYCHOPHARMACOLOGY, 1998, 140 (04) :470-477
[3]   Repeated administration of fluoxetine, desipramine and tranylcypromine increases dopamine D2-like but not D1-like receptor function in the rat [J].
Ainsworth, K ;
Smith, SE ;
Sharp, T .
JOURNAL OF PSYCHOPHARMACOLOGY, 1998, 12 (03) :252-257
[4]  
ALOJADO MES, 1994, ANESTH ANALG, V79, P257
[5]   The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram [J].
Arborelius, L ;
Nomikos, GG ;
Hertel, P ;
Salmi, P ;
Grillner, P ;
Hook, BB ;
Hacksell, U ;
Svensson, TH .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1996, 353 (06) :630-640
[6]   Catecholamine regulation of the prefrontal cortex [J].
Arnsten, AFT .
JOURNAL OF PSYCHOPHARMACOLOGY, 1997, 11 (02) :151-162
[7]   Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].
Artigas, F ;
Romero, L ;
deMontigny, C ;
Blier, P .
TRENDS IN NEUROSCIENCES, 1996, 19 (09) :378-383
[8]  
ASTONJONES G, 1991, PROG BRAIN RES, V88, P501
[9]  
BAKISH D, 1993, J CLIN PSYCHOPHARM, V13, P409
[10]  
Bengtsson HJ, 1999, NORD J PSYCHIAT, V53, P94